secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organon & Co. (OGN)
CIK:        0001821825
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0001104659-26-013888
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organon reports FY2025 rev $6.2B (-3%), GAAP EPS $0.72; guides FY2026 rev ~$6.2B, Adj EBITDA ~$1.9B
--------------------------------------------------------------------------------

- Full year 2025 revenue $6.2B, down 3% YoY; GAAP diluted EPS $0.72, adjusted diluted EPS $3.66.
- Q4 2025 revenue $1.507B (-5% as-reported, -8% ex-FX); Q4 GAAP net loss $205M vs income $109M prior year; adjusted diluted EPS $0.63 vs $0.90.
- Women's Health Q4 revenue down 15%, Nexplanon down 20% ex-FX due to ceased U.S. wholesaler practices and policy access restrictions.
- Biosimilars Q4 revenue up 11%, led by Hadlima and new assets (Bildyos, Bilprevda, Tofidence).
- FY2026 guidance: revenue ~$6.2B, Adjusted EBITDA ~$1.9B, both in line with FY2025 performance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821825/000110465926013888/0001104659-26-013888-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821825/000110465926013888/tm266144d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-013888

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer